NEW YORK, Feb. 13 - Hyseq on Wednesday said that it will license technology from Genetastix to generate fully human monoclonal antibodies against one of its antigens.

Terms of their agreement call for Hyseq to give Genetastix an upfront payment as well as research and development payments to use its HuMYTech technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.